Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported third quarter EPS of $-0.100, better than the analyst estimate of $-0.110. Revenue for the quarter came in at $6.6M versus the consensus estimate of $8.01M.
Abcellera Biologics's stock price closed at $2.89. It is up 4.330% in the last 3 months and down -38.620% in the last 12 months.
Abcellera Biologics saw 2 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Abcellera Biologics's stock price’s past reactions to earnings here.
According to InvestingPro, Abcellera Biologics's Financial Health score is "fair performance".
Check out Abcellera Biologics's recent earnings performance, and Abcellera Biologics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar